ELAN - Elanco Animal Health Incorporated
Elanco Animal Health NYSE: ELAN President and CEO Jeff Simmons outlined the company's growth strategy, product launches, deleveraging plans and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London.
State Street Corp grew its holdings in Elanco Animal Health Incorporated (NYSE: ELAN) by 4.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 16,063,046 shares of the company's stock after purchasing an additional 726,567 shares during the quarter. State Street Corp owned
Elanco Animal Health Incorporated (ELAN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Elanco Animal Health (NYSE: ELAN - Get Free Report) and Amarin (NASDAQ: AMRN - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Volatility and Risk Elanco Animal Health has a
Corient Private Wealth LP lifted its position in shares of Elanco Animal Health Incorporated (NYSE: ELAN) by 124.1% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 342,271 shares of the company's stock after buying an additional 189,540 shares during the period. Corient Private Wealth LP
INDIANAPOLIS, Sept. 17, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the BofA Securities Global Healthcare Conference 2026 on September 22, 2026.
Elanco Animal Health Incorporated (ELAN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Innovation that protects against these pests is driving stronger Elanco base business and overall share gains. Elanco confirms U.S. Pet Health is on track to expectations of high-single digit to low double-digit growth in the second half of 2026.
Squarepoint Ops LLC acquired a new position in shares of Elanco Animal Health Incorporated (NYSE: ELAN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 133,225 shares of the company's stock, valued at approximately $3,279,000. Several other institutional investors and hedge funds
INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2026 financial results on Friday, November 6, 2026.
INDIANAPOLIS, Sept. 10, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026.
The purchase was valued at $936,000. This investment increased the insider's direct equity position by 27%.
Canada Pension Plan Investment Board purchased a new position in Elanco Animal Health Incorporated (NYSE: ELAN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 51,700 shares of the company's stock, valued at approximately $1,272,000. Several other hedge funds and other institutional investors also
Corient Private Wealth LP purchased a new stake in shares of Elanco Animal Health Incorporated (NYSE: ELAN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 348,043 shares of the company's stock, valued at approximately $8,565,000. Corient Private Wealth LP owned approximately
Corient Private Wealth LP raised its stake in Elanco Animal Health Incorporated (NYSE: ELAN) by 127.9% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 348,043 shares of the company's stock after acquiring an additional 195,312 shares during the
Algert Global LLC trimmed its holdings in Elanco Animal Health Incorporated (NYSE: ELAN) by 19.0% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 180,430 shares of the company's stock after selling 42,410 shares during the quarter. Algert Global LLC's holdings
The completed 25,000-square-foot Elwood site expansion bolsters Elanco's monoclonal antibody (mAb) production; supports delivery of next-generation pipeline INDIANAPOLIS, Aug. 26, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the on-time completion of a 25,000-square-foot manufacturing expansion of its Elwood, Kansas manufacturing site. As one of only two animal health companies with mAb solutions on the market today, the expansion further strengthens Elanco's leadership in the biologics space.
I recommend a buy rating for Elanco Animal Health, driven by a strong new product cycle and robust clinic adoption. Zenrelia and Credelio Quattro are gaining significant market share, supporting double-digit revenue growth and margin expansion for ELAN. Befrena offers another growth lever, with early demand exceeding expectations, though near-term contribution is limited by supply constraints.
The director upped their stake by 10,000 shares. This purchase increased the insider's direct equity holdings by 10%.
On CNBC's “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, recommended Netflix, Inc. (NASDAQ:NFLX).